The Priority Review

The stream · Daily digest

The stream: Wednesday, November 11, 2026

7 briefs from the Federal Register, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 4

  1. Argá Medtech completes enrollment of paroxysmal AF cohort in COHERENT-AF

    The company announced that 150 intention-to-treat subjects were enrolled in the paroxysmal atrial fibrillation cohort across 27 sites in Europe and the United States. Enrollment of the persistent AF cohort is ongoing and expected to finish in the next two months.

    Source: Company press release (PR Newswire), November 11, 2026

  2. Lilly reports 52-week results of Taltz and Zepbound in psoriatic arthritis and obesity

    The company said that at one year 43.7% of patients receiving Taltz and Zepbound achieved ACR50 compared with 15.7% for Taltz alone. The 52-week Phase 3b study randomized 271 participants 1:1 to the combination or Taltz monotherapy and reported mild to moderate adverse events consistent with each drug's known safety profile.

    Source: Company press release (PR Newswire), November 11, 2026

  3. Amgen announces positive Phase 3 results for dazodalibep in Sjögren's disease

    Amgen said the Phase 3 OASIZ-301 study met its primary endpoint, with both 1,500 mg every four weeks and 3,000 mg every 12 weeks regimens showing statistically significant reductions in ESSDAI score versus placebo at Week 48. The company noted improvements in patient-reported dryness and that the most common adverse events were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions.

    Source: Company press release (PR Newswire), November 11, 2026

  4. Xtalks hosts webinar on using EHR and applied AI to speed patient recruitment

    The webinar, scheduled for Wednesday, December 2, 2026 at 10am EST, explores how integrating EHR capabilities with applied AI can improve patient identification and reduce manual record review. Speakers include Mike Margiotta of AiSync, Meagan Garvin of Trialbee, and Carl Wolff of Trialbee.

    Source: Company press release (PR Newswire), November 11, 2026

Approvals · 1

  1. Abbisko's PIMJETMI receives U.S. FDA approval for TGCT

    The U.S. FDA approved PIMJETMI as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. The approval follows earlier approvals in China, Canada and Switzerland and is based on the Phase III MANEUVER study showing a 56% objective response rate versus 3% for placebo.

    Source: Company press release (PR Newswire), November 10, 2026

Policy · 1

  1. Zinzino acquires Uzesta to boost distribution capabilities in the APAC region

    Zinzino has acquired the rights to Uzesta Global LLC's distributor database, inventory and intellectual property rights through subsidiaries in Taiwan, Hong Kong and Thailand. The deal includes a fixed purchase price of 0.8 mUSD in cash and a deferred price of 0.4 mUSD, with potential additional payments up to 6.0 mUSD based on future sales.

    Source: Company press release (PR Newswire), November 11, 2026

Regulation · 1

  1. FDA releases draft guidance on early-phase IND protocols for solid tumors

    FDA announced the availability of a draft guidance titled "Early-Phase IND Protocol Recommendations for Solid Tumors" to provide recommendations for sponsors and investigators developing early-phase trials. Comments are due by January 11, 2027, and the guidance covers first-in-human protocols for drugs and biologic products with limited human experience, but does not address hematologic malignancies.

    Source: Federal Register notice, November 12, 2026